What's new in critical illness and injury science? Convalescent plasma for coronavirus disease-2019 patients with severe or critical illness.
作者信息
Miller Andrew Carl, Ghadermarzi Shadi, Venkatachalam Shobi
机构信息
Department of Emergency Medicine, Nazareth Hospital, Philadelphia, PA, USA.
Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.
出版信息
Int J Crit Illn Inj Sci. 2021 Jan-Mar;11(1):1-3. doi: 10.4103/ijciis.ijciis_26_21. Epub 2021 Mar 27.
Abstract
摘要
相似文献
1
What's new in critical illness and injury science? Convalescent plasma for coronavirus disease-2019 patients with severe or critical illness.
Int J Crit Illn Inj Sci. 2021 Jan-Mar;11(1):1-3. doi: 10.4103/ijciis.ijciis_26_21. Epub 2021 Mar 27.
2
What's New in Critical Illness and Injury Science? Alteplase for severe coronavirus disease 2019: Not quite ready to clot bust just hypoxemia.
Int J Crit Illn Inj Sci. 2022 Oct-Dec;12(4):181-183. doi: 10.4103/ijciis.ijciis_82_22. Epub 2022 Dec 26.
3
What's new in critical illness and injury science? Intravenous immunoglobulin for COVID-19 with severe or critical illness.
Int J Crit Illn Inj Sci. 2020 Oct-Dec;10(4):159-162. doi: 10.4103/IJCIIS.IJCIIS_192_20. Epub 2020 Dec 29.
4
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
Cochrane Database Syst Rev. 2020 May 14;5(5):CD013600. doi: 10.1002/14651858.CD013600.
5
What's New in Critical Illness and Injury Science? Delirium, COVID-19, and critical illness.
Int J Crit Illn Inj Sci. 2022 Apr-Jun;12(2):59-60. doi: 10.4103/ijciis.ijciis_44_22. Epub 2022 Jun 24.
6
Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
Clin Microbiol Infect. 2020 Oct;26(10):1436-1446. doi: 10.1016/j.cmi.2020.08.005. Epub 2020 Aug 11.
7
What's New in Critical Illness and Injury Science? Antibiotics in critical care: Therapeutic toolbox.
Int J Crit Illn Inj Sci. 2019 Jul-Sep;9(3):105-109. doi: 10.4103/IJCIIS.IJCIIS_81_19. Epub 2019 Sep 30.
8
Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial.
Crit Care Med. 2021 Jul 1;49(7):1015-1025. doi: 10.1097/CCM.0000000000005066.
9
What's New in Critical Illness and Injury Science? Mortality effects of tocilizumab for patients admitted with COVID-19 pneumonia.
Int J Crit Illn Inj Sci. 2021 Apr-Jun;11(2):49-50. doi: 10.4103/ijciis.ijciis_52_21. Epub 2021 Jun 29.
10
Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial.
Infect Dis Ther. 2020 Dec;9(4):913-926. doi: 10.1007/s40121-020-00341-2. Epub 2020 Sep 20.
引用本文的文献
1
What's new in critical illness and injury science? An evidence-based analysis of the impact of Janus Kinase inhibitors on 28-day mortality in patients admitted with COVID-19.
Int J Crit Illn Inj Sci. 2021 Jul-Sep;11(3):109-111. doi: 10.4103/ijciis.ijciis_80_21. Epub 2021 Sep 25.
2
What's New in Critical Illness and Injury Science? Mortality effects of tocilizumab for patients admitted with COVID-19 pneumonia.
Int J Crit Illn Inj Sci. 2021 Apr-Jun;11(2):49-50. doi: 10.4103/ijciis.ijciis_52_21. Epub 2021 Jun 29.
本文引用的文献
1
Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease.
Sci Rep. 2021 May 11;11(1):9927. doi: 10.1038/s41598-021-89444-5.
2
What's new in critical illness and injury science? Intravenous immunoglobulin for COVID-19 with severe or critical illness.
Int J Crit Illn Inj Sci. 2020 Oct-Dec;10(4):159-162. doi: 10.4103/IJCIIS.IJCIIS_192_20. Epub 2020 Dec 29.
3
Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial.
PLoS Med. 2021 Mar 3;18(3):e1003415. doi: 10.1371/journal.pmed.1003415. eCollection 2021 Mar.
4
Convalescent Plasma Transfusion for the Treatment of COVID-19-Experience from Poland: A Multicenter Study.
J Clin Med. 2020 Dec 24;10(1):28. doi: 10.3390/jcm10010028.
5
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.
N Engl J Med. 2021 Feb 18;384(7):619-629. doi: 10.1056/NEJMoa2031304. Epub 2020 Nov 24.
6
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).
BMJ. 2020 Oct 22;371:m3939. doi: 10.1136/bmj.m3939.
7
A single center cohort of 40 severe COVID-19 patients who were treated with convalescent plasma.
Turk J Med Sci. 2020 Dec 17;50(8):1781-1785. doi: 10.3906/sag-2009-77.
8
[Convalescent plasma therapy in COVID-19 patients, in the Province of Buenos Aires].
Medicina (B Aires). 2020;80(5):417-424.
9
Convalescent plasma therapy in patients with COVID-19.
Transfus Apher Sci. 2021 Feb;60(1):102955. doi: 10.1016/j.transci.2020.102955. Epub 2020 Sep 19.
10
Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study.
Nat Med. 2020 Nov;26(11):1708-1713. doi: 10.1038/s41591-020-1088-9. Epub 2020 Sep 15.
Zotero 插件